T-knife

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.

Total raised

€94M

€93,700,754

Funding rounds

Investors

distinct backers

Active since

2021-08

latest 2021-08

Funding by year

EUR raised per year

High confidence

Raise-next likelihood18

base rate 48% for Series B

Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.

1 rounds

Date	Stage	Amount	Investors
2021-08-02	Series B	€94M	Andera Partners,CaaS Capital Management,Casdin Capital,Fidelity Management & Research Company LLC,LSP,Qatar Investment Authority+3 more	View deal →

same sector or country